12:00 AM
Feb 10, 2014
 |  BioCentury  |  Emerging Company Profile

Amyndas: Complement shutdown

Amyndas developing super compstatins for complement-mediated disorders

Transatlantic sister companies Amyndas Pharmaceuticals S.A. and Amyndas Pharmaceuticals LLC are developing therapies to treat complement-mediated disorders that could be more potent than other complement inhibitors, potentially opening up new indications.

Lead candidate Amanden comes from a class of synthetic analogs of the peptidic complement 3 (C3) inhibitor compstatin, which the company calls super compstatins.

According to founder John Lambris, Amanden is up to several orders of magnitude more potent than first generation compstatin-derived synthetic peptide C3 inhibitors.

The first generation analogs include POT-4, which was discovered in Lambris' lab and licensed to Potentia Pharmaceuticals Inc. in 2006.

Lambris a professor of pathology and laboratory medicine at the University of Pennsylvania, which granted the Amyndas sister companies co-exclusive, worldwide licenses to the super compstatins.

Lambris told BioCentury that super compstatins also have longer plasma half-lives and improved therapeutic properties compared to earlier analogs.

"These significant improvements achieved for the super compstatins...

Read the full 771 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >